<DOC>
	<DOCNO>NCT02450903</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , phase II study evaluate efficacy safety ALK inhibitor LDK378 use single agent patient ALK-rearranged stage IIIB IV NSCLC previously treat alectinib . Treatment LDK378 750 mg qd continue patient experience disease progression determine investigator accord RECIST 1.1 , unacceptable toxicity precludes treatment , pregnancy , start new anticancer therapy , discontinues treatment discretion patient investigator , lose follow-up , death , study terminate Sponsor .</brief_summary>
	<brief_title>LDK378 Patients With ALK Positive NSCLC Previously Treated With Alectinib .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis Stage IIIb IV NSCLC carry ALK rearrangement determine locally Vysis ALK Break Apart FISH Probe Kit ( Abbott Molecular Inc. ) test . Patients must NSCLC progressed study enrollment . Patients must receive previous treatment alectinib treatment locally advance metastatic NSCLC . Prior therapy crizotinib ALK inhibitor therapy addition alectinib allow . Alectinib n't need last therapy prior study enrollment . No particular sequence prior alectinib crizotinib require enrollment . Patients must chemotherapyna√Øve receive one line prior cytotoxic chemotherapy . Age 18 year old time inform consent . Patients know hypersensitivity excipients LDK378 . Prior therapy ALK inhibitor investigational agent except crizotinib alectinib . Prior systemic anticancer ( include investigational ) therapy aside alectinib , crizotinib one regimen previous cytotoxic chemotherapy locally advance metastatic NSCLC . Patients symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid within 2 week prior study entry manage CNS symptom . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis . Ptients history carcinomatous meningitis . Patient concurrent malignancy history malignant disease NSCLC diagnose and/or require therapy within past 3 year . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Small-Cell Lung Cancer , ALK , LDK378</keyword>
</DOC>